Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.

Name: Kaimen Rigor review — Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Item: Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Rating: 100
Author: Alpha1

Basch E, Schrag D, Jansen J, Henson S, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak L, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Wolf AP, Dueck AC

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 4★ (Strong), 0 critical, 2 high issues for “Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03507-y

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/982f5e00-abc1-4544-90ff-1d13d4c6d492" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/982f5e00-abc1-4544-90ff-1d13d4c6d492/badge" alt="Kaimen Rigor review — 4★ (Strong), 0 critical, 2 high issues for “Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

d3ef6103c1f72ad09a0f3dd6ab426eae454baaedce9b541dbd5dee36c2b657ec

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.

Paper source

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on secondary outcomes including time to deterioration of physical function, symptom control, and HRQL, which are patient-reported outcome measures (surrogates for clinical benefit). The paper does not provide evidence of target engagement at the tested dose (since it's a behavioral intervention, not a drug) nor does it cite validated evidence linking these PRO measures to hard clinical outcomes. The primary outcome of overall survival was not significant, so the efficacy claim rests on these surrogate endpoints.
“Benefits also significantly favored PRO for delayed deterioration of physical function (median 12.6 versus 8.5 months, HR 0.73; P = 0.002), symptoms (12.7 versus 9.9, HR 0.69; P < 0.001) and HRQL (15.6 versus 12.2, HR 0.72; P = 0.001)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes for the surrogate outcomes (e.g., HR 0.73 for physical function deterioration) are presented as statistically significant but are not anchored to a minimal clinically important difference or to a clear biological/clinical meaningfulness. The paper does not provide a threshold for clinical significance for these HRs, and the absolute differences in median times (e.g., 4.1 months for physical function) are not explicitly interpreted as clinically meaningful. The primary outcome (overall survival) showed no effect, so the meaningfulness of the secondary effects is not established.
“Time to deterioration in physical function was statistically significantly longer in the PRO group compared to the control group, with a median time of 12.6 months versus 8.5 months (HR 0.73; P = 0.002).”
Find in source

Findings by category

01ArithmeticNone found 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported multicenter cluster-randomized trial. The methods are rigorous, with clear randomization, power analysis, and prespecified criteria, and the reporting is thorough with trial registration, data availability, and limitations discussed. Minor reporting gaps include lack of explicit blinding rationale, outlier handling, and a Declaration of Helsinki statement, plus a few copyedit issues.

Both reviewers independently scored all eight dimensions as pass, with high agreement. The study is an interventional cluster-randomized trial; no divergence in study type. Non-applicable criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 2 tests due to limited machine-verifiable statistics; the rest were not independently recomputed.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple prior trials and observational studies (STAR, CAPRI, Canadian population-based study) and discusses their strengths and limitations. The rationale for the trial is clearly linked to the objective of evaluating PRO symptom monitoring in a national US community oncology setting. The paper also addresses limitations of prior research, such as the single-center nature of STAR and the need for a multicenter trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and acknowledgment of prior limitations.

Evidence

paraphrase[Introduction, paragraph 2]

“Prior prospective trials and observational studies have reported benefits of implementing such electronic PRO symptom monitoring systems on quality of life outcomes, emergency department and hospital utilization and in some cases survival among patients receiving cancer treatment.”

paraphrase[Introduction, paragraph 3]

“To complement this body of evidence with a national trial in the United States, and modeled on the approach used in the STAR study, a multicenter cluster-randomized trial, PRO-TECT (Alliance AFT-39; NCT03249090), was designed and conducted in 52 community oncology practices to evaluate the real-world impact of electronic PRO symptom monitoring on clinical outcomes compared to usual care.”

paraphrase[Introduction, paragraph 3]

“A Canadian population-based observational study among more than 128,000 patients with cancer who either participated or did not participate in PRO symptom monitoring similarly found a statistically significant 8% reduction in emergency visits and a 14% reduction in hospitalizations associated with PRO.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 2]

paraphrase[Introduction, paragraph 3]

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”

Discussion ¶4Find in source

Randomization method (permuted blocks, stratified by rural/urban) and unit (oncology practices) are clearly described. Blinding is not explicitly described, but the cluster-randomized design makes blinding of practices infeasible; the paper does not state whether outcome assessors were blinded, which is a minor gap. A power analysis is provided with effect size, alpha, and power. Inclusion/exclusion criteria are prespecified. Outlier handling is not explicitly discussed, but the analysis population is defined (all randomized patients). Controls are the usual care group. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, blinding considerations, power analysis, and prespecified inclusion/exclusion criteria.

Evidence

“Participating practices were randomly assigned 1:1 to electronic PRO symptom monitoring (intervention) or usual care (control) using permuted blocks with block sizes of 2 or 4 and stratified by rural/urban based on US Census Bureau criteria.”

MethodsFind in source

paraphrase[Methods, Sample size calculation]

“This sample size provided 90% power for an overall survival hazard ratio of 0.76 based on prior research using a two-sided alpha of 0.05 log-rank test with 576 observed events, computed using the formula by Xie and Waksman, with an intracluster correlation coefficient of 0.001 (based on prior trials), assuming dropout of 150 patients in the first 2.5 years.”

“Each practice could enroll up to 50 consecutively approached adults (aged 21 years or older) with any type of metastatic cancer receiving outpatient systemic antineoplastic treatment (including immuno-therapy, targeted oral therapy or chemotherapy), if they understood English, Spanish or Mandarin.”

MethodsFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with clear randomization, blinding considerations, power analysis, and prespecified inclusion/exclusion criteria.

Evidence

MethodsFind in source

paraphrase[Methods, Sample size calculation]

paraphrase[Methods, Patients and inclusion criteria]

“Each practice could enroll up to 50 consecutively approached adults (aged 21 years or older) with any type of metastatic cancer receiving outpatient systemic antineoplastic treatment (including immunotherapy, targeted oral therapy or chemotherapy), if they understood English, Spanish or Mandarin.”

Sex, age, race, ethnicity, education, employment, rural location, marital status, technology use, and cancer type are reported in Table 1. Health status is implied by cancer type and line of therapy. Species/strain and housing conditions are not applicable for a human trial. Demographics are comprehensive.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, education, and cancer type.

Evidence

paraphrase[Table 1]

“Age, median (range), years | 64 (29–89) | 62 (28–93) | Sex | Female | 359/593 (60.5%) | 335/597 (56.1%)”

paraphrase[Table 1]

“Race (regardless of ethnicity) | American Indian or Alaska Native | 11/588 (1.9%) | 13/576 (2.3%)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are comprehensively reported, including sex, age, race, education, and cancer type.

Evidence

“Age, median (range), years | 64 (29–89) | 62 (28–93) | | Sex | | Female | 359/593 (60.5%) | 335/597 (56.1%)”

Table 1Find in source

paraphrase[Table 1]

“Race (regardless of ethnicity) | American Indian or Alaska Native | 11/588 (1.9%) | 13/576 (2.3%)”

paraphrase[Table 1]

“Cancer type | Colorectal, anal | 100 (16.9%) | 132 (22.1%)”

The paper states that all patients signed written informed consent and that the protocol was approved by the University of North Carolina IRB (IRB Number 17–1864), Quorum central IRB (IRB number 32498), and Advarra central IRB (IRB number Pro00043507). Regulatory compliance is implied by adherence to IRB approvals, though no explicit statement of compliance with the Declaration of Helsinki is present, but this is not required for adequacy.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and informed consent are clearly documented with named IRBs and protocol numbers.

Evidence

“The protocol and consent were approved by the Institutional Review Board (IRB) of the University of North Carolina (IRB Number 17–1864), as well as the Quorum central IRB (IRB number 32498) and the Advarra central IRB (IRB number Pro00043507).”

MethodsFind in source

“All patient participants signed written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and informed consent are clearly documented with named IRBs and protocol numbers.

Evidence

MethodsFind in source

“All patient participants signed written informed consent.”

MethodsFind in source

The PRO monitoring system is described in detail, including the PRO-CTCAE item library and other instruments. The EORTC QLQ-C30 is identified. Statistical software (SAS v9.4) is named. No antibodies, cell lines, or mycoplasma testing are applicable. The PRO system is not a drug/device but a software intervention; it is adequately described.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (PRO monitoring system) and key questionnaires are identified, and software is named.

Evidence

paraphrase[Methods, Intervention]

“This system administers surveys to patients with symptom questions from the National Cancer Institute’s PRO-CTCAE, item library including constipation, diarrhea, dyspnea, insomnia, nausea, pain, and vomiting; as well as a depression item from the PHQ-2; an oral intake (eating and drinking) item; physical function from the patient-reported version of Eastern Cooperative Oncology Group performance status; falls; and financial toxicity from the COST questionnaire.”

“Statistical testing was two sided, with P values < 0.05 considered statistically significant, and carried out in SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (PRO monitoring system) is described in detail, and the software used for analysis is identified.

Evidence

paraphrase[Methods, Intervention]

“This system administers surveys to patients with symptom questions from the National Cancer Institute’s PRO-CTCAE item library including constipation, diarrhea, dyspnea, insomnia, nausea, pain, and vomiting; as well as a depression item from the PHQ-2; an oral intake (eating and drinking) item; physical function from the patient-reported version of Eastern Cooperative Oncology Group performance status; falls; and financial toxicity from the COST questionnaire.”

“Statistical testing was two sided, with P values < 0.05 considered statistically significant, and carried out in SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

All statistical tests are named (Cox regression, Fine-Gray competing risk, mixed models). Assumptions are handled by design (e.g., competing risk for death). Exact p-values are reported for primary and secondary outcomes. Effect sizes with confidence intervals are reported. Software is identified. Data presentation includes Kaplan-Meier curves and per-group n. Mathematical plausibility checks were not possible for most outcomes due to continuous data and model-based estimates, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“The outcome of overall survival was analyzed via Cox regression using prespecified covariates of months since initial diagnosis to development of metastases, months since initial diagnosis to first systemic cancer treatment, line of sustemic cancer treatment, months since developing metastases to date of trial enrollment and a random effect for site clustering.”

Statistical analysisFind in source

“There was no statistically significant difference between study groups in this outcome at 2 years with an HR (HR) of 0.99 (95% confidence interval (CI) 0.83–1.17, P = 0.86).”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical analysis]

“The outcome of overall survival was analyzed via Cox regression using prespecified covariates of months since initial diagnosis to development of metastases, months since initial diagnosis to first systemic cancer treatment, line of systemic cancer treatment, months since developing metastases to date of trial enrollment and a random effect for site clustering.”

“there was no difference in survival (hazard ratio (HR) 0.99 (95% confidence interval (CI), 0.83–1.17); P = 0.86).”

AbstractFind in source

paraphrase[Results, Emergency department visits]

“Time to first emergency department visit was statistically significantly prolonged (improved) in the PRO intervention group compared to usual care, with an HR of 0.84 (95% CI, 0.71–0.98, P = 0.03).”

The data availability statement provides a specific mechanism for requesting deidentified participant data via the Alliance's data sharing process, including a URL and contact email. This is a managed-access route, which is appropriate for patient-level data. No code was generated for analysis, so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is clearly stated with a concrete access route through the Alliance for Clinical Trials in Oncology.

Evidence

“Individual deidentified participant data for this trial, including data dictionaries and all variables from analyses in this publication, are available through the Alliance for Clinical Trials in Oncology. Data Sharing Requests may be submitted at: https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FDatasharing”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly stated with a concrete access mechanism through the Alliance for Clinical Trials in Oncology.

Evidence

Data availabilityFind in source

The trial is registered at ClinicalTrials.gov (NCT03249090). Methods are detailed enough for replication. A reporting guideline is referenced (Nature Portfolio Reporting Summary). All prespecified outcomes are reported, including negative results (overall survival). Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are complete, limitations are discussed, and conclusions are proportional.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) registration: NCT03249090 (https://clinicaltrials.gov/ct2/show/NCT03249090)”

AbstractFind in source

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”

Discussion ¶6Find in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) registration: NCT03249090 (https://clinicaltrials.gov/ct2/show/NCT03249090)”

AbstractFind in source

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”

Discussion ¶4Find in source

“This trial was funded by the Patient-Centered Outcomes Research Institute (PCORI) IHS-1511-33392, with research support from this grant provided to all authors listed on this manuscript except V.B. and A.W.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 44 references by DOI: 39 verified — 5 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (blinding rationale, outlier handling, explicit ethics framework statement) as areas for potential clarification but they do not undermine the study's conclusions. No erratum appears warranted based on the checks performed; the copyedit issues are minor and do not affect scientific integrity.

1.
HIGHreporting
Add an explicit statement in the Methods (Randomization or Limitations) explaining that blinding of practices and patients was not feasible due to the cluster-randomized design, and acknowledge this as a potential source of bias in the Discussion.
Both reviewers flagged the lack of explicit blinding rationale as a minor gap; adding it improves transparency and addresses a common reviewer concern.
2.
HIGHreporting
Add a sentence in the Methods (Statistical analysis) describing how outliers and missing data were handled, or state that no outliers were excluded and missing data were handled as per the analysis population.
Both reviewers noted outlier handling was not explicitly discussed; clarifying this strengthens the statistical reporting.
3.
MEDIUMethics
Add a statement in the Ethics section confirming compliance with the Declaration of Helsinki or other relevant ethical guidelines.
Reviewer 2 flagged regulatory_compliance as reported_but_inadequate due to lack of explicit ethical framework statement; adding it resolves the minor gap.
4.
MEDIUMcopyedit
Fix the typo 'sustemic' to 'systemic' in the Methods, Statistical analysis section.
Copyedit pass flagged this typo; correcting it improves professionalism.
5.
MEDIUMcopyedit
Clarify in the Abstract that the 77.0% (188/244) satisfaction figure refers to the off-study assessment, not the 3-month assessment, to avoid ambiguity.
Copyedit pass noted inconsistency between abstract and results regarding the time point for satisfaction percentages.
6.
LOWdata code
Consider providing the statistical analysis code (e.g., SAS scripts) in a public repository to enhance reproducibility.
Reviewer 2 suggested sharing code; while not required, it would strengthen reproducibility.
7.
LOWreporting
Add a note in the Data Availability section about the expected timeframe for responding to data requests.
Reviewer 2 suggested this to set expectations for data requesters.
8.
LOWreporting
Consider including a CONSORT flow diagram in the main text to enhance reporting transparency.
Reviewer 1 suggested this; while not essential, it improves adherence to reporting guidelines.
9.
LOWreporting
Provide the statistical analysis plan as a supplementary file to enhance transparency.
Reviewer 1 suggested this; it would allow readers to verify prespecified analyses.

Full text (52,639 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03507-y

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/982f5e00-abc1-4544-90ff-1d13d4c6d492" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/982f5e00-abc1-4544-90ff-1d13d4c6d492/badge" alt="Kaimen Rigor review — 4★ (Strong), 0 critical, 2 high issues for “Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

d3ef6103c1f72ad09a0f3dd6ab426eae454baaedce9b541dbd5dee36c2b657ec

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on secondary outcomes including time to deterioration of physical function, symptom control, and HRQL, which are patient-reported outcome measures (surrogates for clinical benefit). The paper does not provide evidence of target engagement at the tested dose (since it's a behavioral intervention, not a drug) nor does it cite validated evidence linking these PRO measures to hard clinical outcomes. The primary outcome of overall survival was not significant, so the efficacy claim rests on these surrogate endpoints.
“Benefits also significantly favored PRO for delayed deterioration of physical function (median 12.6 versus 8.5 months, HR 0.73; P = 0.002), symptoms (12.7 versus 9.9, HR 0.69; P < 0.001) and HRQL (15.6 versus 12.2, HR 0.72; P = 0.001)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes for the surrogate outcomes (e.g., HR 0.73 for physical function deterioration) are presented as statistically significant but are not anchored to a minimal clinically important difference or to a clear biological/clinical meaningfulness. The paper does not provide a threshold for clinical significance for these HRs, and the absolute differences in median times (e.g., 4.1 months for physical function) are not explicitly interpreted as clinically meaningful. The primary outcome (overall survival) showed no effect, so the meaningfulness of the secondary effects is not established.
“Time to deterioration in physical function was statistically significantly longer in the PRO group compared to the control group, with a median time of 12.6 months versus 8.5 months (HR 0.73; P = 0.002).”
Find in source

Findings by category

01ArithmeticNone found 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and acknowledgment of prior limitations.

Evidence

paraphrase[Introduction, paragraph 2]

paraphrase[Introduction, paragraph 3]

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 2]

paraphrase[Introduction, paragraph 3]

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”

Discussion ¶4Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, blinding considerations, power analysis, and prespecified inclusion/exclusion criteria.

Evidence

MethodsFind in source

paraphrase[Methods, Sample size calculation]

MethodsFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with clear randomization, blinding considerations, power analysis, and prespecified inclusion/exclusion criteria.

Evidence

MethodsFind in source

paraphrase[Methods, Sample size calculation]

paraphrase[Methods, Patients and inclusion criteria]

“Each practice could enroll up to 50 consecutively approached adults (aged 21 years or older) with any type of metastatic cancer receiving outpatient systemic antineoplastic treatment (including immunotherapy, targeted oral therapy or chemotherapy), if they understood English, Spanish or Mandarin.”

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, education, and cancer type.

Evidence

paraphrase[Table 1]

“Age, median (range), years | 64 (29–89) | 62 (28–93) | Sex | Female | 359/593 (60.5%) | 335/597 (56.1%)”

paraphrase[Table 1]

“Race (regardless of ethnicity) | American Indian or Alaska Native | 11/588 (1.9%) | 13/576 (2.3%)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are comprehensively reported, including sex, age, race, education, and cancer type.

Evidence

“Age, median (range), years | 64 (29–89) | 62 (28–93) | | Sex | | Female | 359/593 (60.5%) | 335/597 (56.1%)”

Table 1Find in source

paraphrase[Table 1]

“Race (regardless of ethnicity) | American Indian or Alaska Native | 11/588 (1.9%) | 13/576 (2.3%)”

paraphrase[Table 1]

“Cancer type | Colorectal, anal | 100 (16.9%) | 132 (22.1%)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and informed consent are clearly documented with named IRBs and protocol numbers.

Evidence

MethodsFind in source

“All patient participants signed written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and informed consent are clearly documented with named IRBs and protocol numbers.

Evidence

MethodsFind in source

“All patient participants signed written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (PRO monitoring system) and key questionnaires are identified, and software is named.

Evidence

paraphrase[Methods, Intervention]

“Statistical testing was two sided, with P values < 0.05 considered statistically significant, and carried out in SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (PRO monitoring system) is described in detail, and the software used for analysis is identified.

Evidence

paraphrase[Methods, Intervention]

“Statistical testing was two sided, with P values < 0.05 considered statistically significant, and carried out in SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

Statistical analysisFind in source

“There was no statistically significant difference between study groups in this outcome at 2 years with an HR (HR) of 0.99 (95% confidence interval (CI) 0.83–1.17, P = 0.86).”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical analysis]

“The outcome of overall survival was analyzed via Cox regression using prespecified covariates of months since initial diagnosis to development of metastases, months since initial diagnosis to first systemic cancer treatment, line of systemic cancer treatment, months since developing metastases to date of trial enrollment and a random effect for site clustering.”

“there was no difference in survival (hazard ratio (HR) 0.99 (95% confidence interval (CI), 0.83–1.17); P = 0.86).”

AbstractFind in source

paraphrase[Results, Emergency department visits]

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is clearly stated with a concrete access route through the Alliance for Clinical Trials in Oncology.

Evidence

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly stated with a concrete access mechanism through the Alliance for Clinical Trials in Oncology.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is registered, methods are complete, limitations are discussed, and conclusions are proportional.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) registration: NCT03249090 (https://clinicaltrials.gov/ct2/show/NCT03249090)”

AbstractFind in source

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”

Discussion ¶6Find in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) registration: NCT03249090 (https://clinicaltrials.gov/ct2/show/NCT03249090)”

AbstractFind in source

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”

Discussion ¶4Find in source

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 44 references by DOI: 39 verified — 5 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Add an explicit statement in the Methods (Randomization or Limitations) explaining that blinding of practices and patients was not feasible due to the cluster-randomized design, and acknowledge this as a potential source of bias in the Discussion.
Both reviewers flagged the lack of explicit blinding rationale as a minor gap; adding it improves transparency and addresses a common reviewer concern.
2.
HIGHreporting
Add a sentence in the Methods (Statistical analysis) describing how outliers and missing data were handled, or state that no outliers were excluded and missing data were handled as per the analysis population.
Both reviewers noted outlier handling was not explicitly discussed; clarifying this strengthens the statistical reporting.
3.
MEDIUMethics
Add a statement in the Ethics section confirming compliance with the Declaration of Helsinki or other relevant ethical guidelines.
Reviewer 2 flagged regulatory_compliance as reported_but_inadequate due to lack of explicit ethical framework statement; adding it resolves the minor gap.
4.
MEDIUMcopyedit
Fix the typo 'sustemic' to 'systemic' in the Methods, Statistical analysis section.
Copyedit pass flagged this typo; correcting it improves professionalism.
5.
MEDIUMcopyedit
Clarify in the Abstract that the 77.0% (188/244) satisfaction figure refers to the off-study assessment, not the 3-month assessment, to avoid ambiguity.
Copyedit pass noted inconsistency between abstract and results regarding the time point for satisfaction percentages.
6.
LOWdata code
Consider providing the statistical analysis code (e.g., SAS scripts) in a public repository to enhance reproducibility.
Reviewer 2 suggested sharing code; while not required, it would strengthen reproducibility.
7.
LOWreporting
Add a note in the Data Availability section about the expected timeframe for responding to data requests.
Reviewer 2 suggested this to set expectations for data requesters.
8.
LOWreporting
Consider including a CONSORT flow diagram in the main text to enhance reporting transparency.
Reviewer 1 suggested this; while not essential, it improves adherence to reporting guidelines.
9.
LOWreporting
Provide the statistical analysis plan as a supplementary file to enhance transparency.
Reviewer 1 suggested this; it would allow readers to verify prespecified analyses.

Full text (52,639 chars)Analyzed: Aug 15, 2026